BRAF and cardiomyopathy: Cardiomyopathy leading to heart failure is a serious adverse effect of treatment with various classes of KIs, including BCR-ABL kinase (e.g., dasatinib, imatinib), c-KIT (ripretinib, imatinib), BRAF/MEK, EGFR, and ALK inhibitors, as well as multitarget KIs used for mRCC treatment.